Testosterone and cardiovascular diseases
Several meta-analyses were subsequently published pooling data from controlled trials, mostly reporting CV safety of TT, although no definitive conclusion could be drawn because of inhomogeneity of patient population, lack of adequate statistical power, and many low-medium quality studies involved.
*On this basis, in 2018 the TRAVERSE trial was implemented, aimed at evaluating the effect of TT on MACE and efficacy measures in hypogonadal men (NCT03518034). The adequate statistical power of the trial enrolling 6,000 men will hopefully provide next year (2022) a definitive answer to the outstanding issue of CV safety of TT.
